Payments to Acquire Property, Plant, and Equipment of ImmunoGen, Inc. from 30 Jun 2010 to 31 Mar 2023

Taxonomy & unit
us-gaap: USD
Description
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
Summary
ImmunoGen, Inc. quarterly and annual Payments to Acquire Property, Plant, and Equipment in USD history and change rate from 30 Jun 2010 to 31 Mar 2023.
  • ImmunoGen, Inc. Payments to Acquire Property, Plant, and Equipment for the quarter ending 31 Mar 2023 was $209,000, a 32% decline year-over-year.
  • ImmunoGen, Inc. annual Payments to Acquire Property, Plant, and Equipment for 2022 was $1,364,000, a 4.9% decline from 2021.
  • ImmunoGen, Inc. annual Payments to Acquire Property, Plant, and Equipment for 2021 was $1,434,000, a 56% increase from 2020.
  • ImmunoGen, Inc. annual Payments to Acquire Property, Plant, and Equipment for 2020 was $917,000, a 68% decline from 2019.
Source SEC data
View on sec.gov
Payments to Acquire Property, Plant, and Equipment, Quarterly (USD)
Payments to Acquire Property, Plant, and Equipment, YoY Quarterly Change (%)
Payments to Acquire Property, Plant, and Equipment, Annual (USD)
Payments to Acquire Property, Plant, and Equipment, YoY Annual Change (%)

ImmunoGen, Inc. Quarterly Payments to Acquire Property, Plant, and Equipment (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2023 $209,000 -$98,000 -32% 01 Jan 2023 31 Mar 2023 10-Q 28 Apr 2023 2023 Q1
Q1 2022 $307,000 -$586,000 -66% 01 Jan 2022 31 Mar 2022 10-Q 28 Apr 2023 2023 Q1
Q1 2021 $893,000 +$872,000 +4152% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q1 2020 $21,000 -$2,106,000 -99% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q1 2019 $2,127,000 +$1,099,000 +107% 01 Jan 2019 31 Mar 2019 10-Q 05 May 2020 2020 Q1
Q1 2018 $1,028,000 +$591,000 +135% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q1 2017 $437,000 -$3,042,000 -87% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q3 2016 $1,182,000 -$2,195,000 -65% 01 Jul 2016 30 Sep 2016 10-Q 04 Nov 2016 2017 Q1
Q1 2016 $3,479,000 01 Jan 2016 31 Mar 2016 10-Q 05 May 2017 2017 Q1
Q3 2015 $3,377,000 +$1,669,000 +98% 01 Jul 2015 30 Sep 2015 10-Q 04 Nov 2016 2017 Q1
Q3 2014 $1,708,000 +$1,136,000 +199% 01 Jul 2014 30 Sep 2014 10-Q 30 Oct 2015 2016 Q1
Q3 2013 $572,000 -$394,000 -41% 01 Jul 2013 30 Sep 2013 10-Q 30 Oct 2014 2015 Q1
Q3 2012 $966,000 +$412,000 +74% 01 Jul 2012 30 Sep 2012 10-Q 29 Oct 2013 2014 Q1
Q3 2011 $554,000 +$206,000 +59% 01 Jul 2011 30 Sep 2011 10-Q 31 Oct 2012 2013 Q1
Q3 2010 $348,000 01 Jul 2010 30 Sep 2010 10-Q 31 Oct 2011 2012 Q1

ImmunoGen, Inc. Annual Payments to Acquire Property, Plant, and Equipment (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2022 $1,364,000 -$70,000 -4.9% 01 Jan 2022 31 Dec 2022 10-K 01 Mar 2023 2022 FY
2021 $1,434,000 +$517,000 +56% 01 Jan 2021 31 Dec 2021 10-K 01 Mar 2023 2022 FY
2020 $917,000 -$1,928,000 -68% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
2019 $2,845,000 -$2,401,000 -46% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $5,246,000 +$4,130,000 +370% 01 Jan 2018 31 Dec 2018 10-K 01 Mar 2021 2020 FY
2017 $1,116,000 -$9,260,000 -89% 01 Jan 2017 31 Dec 2017 10-K 11 Mar 2020 2019 FY
2016 $10,376,000 +$2,951,000 +40% 01 Jul 2015 30 Jun 2016 10-K 01 Mar 2019 2018 FY
2015 $7,425,000 -$759,000 -9.3% 01 Jul 2014 30 Jun 2015 10-K 07 Mar 2018 2017 FY
2014 $8,184,000 +$4,414,000 +117% 01 Jul 2013 30 Jun 2014 10-KT 03 Mar 2017 2016 FY
2013 $3,770,000 +$862,000 +30% 01 Jul 2012 30 Jun 2013 10-K 27 Aug 2015 2015 FY
2012 $2,908,000 +$879,000 +43% 01 Jul 2011 30 Jun 2012 10-K 28 Aug 2014 2014 FY
2011 $2,029,000 +$495,000 +32% 01 Jul 2010 30 Jun 2011 10-K 29 Aug 2013 2013 FY
2010 $1,534,000 01 Jul 2009 30 Jun 2010 10-K 29 Aug 2012 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.